752 related articles for article (PubMed ID: 23519301)
1. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
Massad LS; Einstein MH; Huh WK; Katki HA; Kinney WK; Schiffman M; Solomon D; Wentzensen N; Lawson HW;
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S1-S27. PubMed ID: 23519301
[TBL] [Abstract][Full Text] [Related]
2. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
Massad LS; Einstein MH; Huh WK; Katki HA; Kinney WK; Schiffman M; Solomon D; Wentzensen N; Lawson HW;
Obstet Gynecol; 2013 Apr; 121(4):829-846. PubMed ID: 23635684
[TBL] [Abstract][Full Text] [Related]
3. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
Cox JT;
Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
[TBL] [Abstract][Full Text] [Related]
4. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.
Wright TC; Massad LS; Dunton CJ; Spitzer M; Wilkinson EJ; Solomon D;
J Low Genit Tract Dis; 2007 Oct; 11(4):223-39. PubMed ID: 17917567
[TBL] [Abstract][Full Text] [Related]
5. 2006 consensus guidelines for the management of women with abnormal cervical screening tests.
Wright TC; Massad LS; Dunton CJ; Spitzer M; Wilkinson EJ; Solomon D;
J Low Genit Tract Dis; 2007 Oct; 11(4):201-22. PubMed ID: 17917566
[TBL] [Abstract][Full Text] [Related]
6. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
[TBL] [Abstract][Full Text] [Related]
7. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
[TBL] [Abstract][Full Text] [Related]
8. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
[TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
10. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests.
Wright TC; Massad LS; Dunton CJ; Spitzer M; Wilkinson EJ; Solomon D;
Am J Obstet Gynecol; 2007 Oct; 197(4):346-55. PubMed ID: 17904957
[TBL] [Abstract][Full Text] [Related]
11. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities.
Wright TC; Cox JT; Massad LS; Twiggs LB; Wilkinson EJ;
JAMA; 2002 Apr; 287(16):2120-9. PubMed ID: 11966387
[TBL] [Abstract][Full Text] [Related]
12. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303
[TBL] [Abstract][Full Text] [Related]
13. Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion.
Ryu KJ; Lee S; Min KJ; Kim JW; Hong JH; Song JY; Lee JK; Lee NW
Oncologist; 2015 Jun; 20(6):635-9. PubMed ID: 25964305
[TBL] [Abstract][Full Text] [Related]
14. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
15. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
16. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.
Demarco M; Lorey TS; Fetterman B; Cheung LC; Guido RS; Wentzensen N; Kinney WK; Poitras NE; Befano B; Castle PE; Schiffman M
J Low Genit Tract Dis; 2017 Oct; 21(4):261-267. PubMed ID: 28953116
[TBL] [Abstract][Full Text] [Related]
17. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
[TBL] [Abstract][Full Text] [Related]
18. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Triage for Atypical Squamous Cells of Undetermined Significance with Human Papillomavirus Testing in Cervical Cancer Screening in Japan.
Fujiwara H; Suzuki M; Morisawa H; Sayama M; Kimura K
Asian Pac J Cancer Prev; 2019 Jan; 20(1):81-85. PubMed ID: 30678384
[TBL] [Abstract][Full Text] [Related]
20. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
